Key Takeaways
- Multiple myeloma is a blood cancer that weakens the immune system, making infections a major risk for patients.
- IVIG (intravenous immunoglobulin) replaces missing antibodies to help reduce the risk of serious and recurrent infections.
- IVIG is typically recommended for myeloma patients with low immunoglobulin levels and a history of frequent infections.
- Treatment involves regular infusions, usually every 3 to 4 weeks, given at a specialized infusion center.
- Suite Life partners with oncologists across Massachusetts and Rhode Island, including new locations in Westfield and Westborough, to deliver IVIG and supportive infusion therapy. Request an appointment to coordinate your care.
Multiple Myeloma and the Immune System
Multiple myeloma is a cancer of the plasma cells, a type of white blood cell normally responsible for producing antibodies that fight infection. According to the American Cancer Society, approximately 35,780 new cases of multiple myeloma are estimated to be diagnosed in the United States in 2024.
When plasma cells become cancerous, they crowd out healthy blood cells and produce large amounts of the same protein (M proteins) instead of the diverse antibodies the body needs to defend itself. The result is a condition called hypogammaglobulinemia, in which overall antibody levels drop, and patients are left vulnerable to bacterial, viral, and fungal infections.
The International Myeloma Foundation notes that infections are among the leading causes of complications and hospitalization in patients with multiple myeloma, particularly during the first few months after diagnosis and during periods of active treatment.
What Is IVIG?
IVIG, or intravenous immunoglobulin, is a therapy that delivers concentrated antibodies (mainly G) directly into the bloodstream. These antibodies are pooled from thousands of healthy donors and processed to provide a broad spectrum of immune protection.
For multiple myeloma patients, IVIG works as an antibody replacement therapy. By restoring the protective antibodies their immune system can no longer make, IVIG helps reduce the risk of severe and recurrent infections.
How IVIG Helps Prevent Infections in Multiple Myeloma Patients
The benefits of IVIG go beyond simple antibody replacement. By supporting immune function during a vulnerable time, IVIG helps multiple myeloma patients:
- Reduce the frequency of bacterial respiratory infections like pneumonia
- Decrease the need for hospital admissions
- Maintain quality of life during active cancer treatment
- Better tolerate ongoing myeloma therapy
The Cleveland Clinic notes that IVIG is often considered for patients with antibody deficiencies who experience recurrent infections despite preventive antibiotic therapy.
When Is IVIG Recommended During Multiple Myeloma Treatment?
IVIG is not used in every multiple myeloma case. Oncologists typically recommend it when specific criteria are met.
Recurrent or Severe Infections
If a patient has had two or more serious bacterial infections within a year despite vaccinations and preventive antibiotics, IVIG may be considered.
Low IgG Levels
Patients with persistently low IgG levels (often below 400 mg/dL) are at higher risk for infection. Blood tests confirm whether antibody replacement is necessary.
During Active Myeloma Treatment
Some therapies for multiple myeloma, such as bispecific antibody drugs and CAR-T cell therapy, can further suppress immune function. IVIG may be initiated during these periods to provide additional protection.
Following Stem Cell Transplant
In the months after an autologous stem cell transplant, the immune system is slow to recover. IVIG support during this window can help prevent serious infections.
The IVIG Infusion Protocol: What to Expect
The standard IVIG infusion protocol for multiple myeloma patients is typically every 3 to 4 weeks, though dosing and frequency are tailored to each patient.
| Step | Description | Approximate Time |
|---|---|---|
| Pre-infusion check | Vital signs, hydration, and lab review | 15 to 30 minutes |
| Infusion | IV administration of immunoglobulin | 2 to 4 hours |
| Observation | Monitoring for reactions | 30 minutes |
| Follow-up labs | IgG levels are checked periodically | As scheduled |
Most patients tolerate IVIG well, though some may experience mild side effects such as headache, fatigue, low-grade fever, or muscle aches during or after the infusion. These reactions are usually short-lived and can often be minimized by slowing the infusion rate or premedicating with acetaminophen or antihistamines.
Benefits of IVIG for Quality of Life and Reduced Hospitalizations
For multiple myeloma patients, the impact of IVIG extends far beyond the lab values. Reducing infection risk means:
- Fewer disruptions to cancer treatment schedules
- More time at home with family and less time in the hospital
- Reduced exposure to antibiotic side effects
- Less anxiety about routine illness exposure
Suite Life Health and Wellness coordinates closely with oncology teams to ensure that IVIG and other supportive infusion therapies are administered safely and on schedule, helping patients stay focused on their broader cancer treatment plan.
What to Expect During IVIG Therapy at Suite Life
When you arrive at Suite Life Health and Wellness, you will be welcomed into a private suite designed for comfort. Each suite features:
- A reclining chair with personal space and privacy
- Wi-Fi and entertainment options
- Climate control and quiet surroundings
- Trained infusion nurses are available throughout your visit
Your oncologist will work with the Suite Life team to develop a treatment plan, including dosing, schedule, and any premedications needed to reduce side effects. Suite Life now serves even more patients with locations in Westfield and Westborough, in addition to its existing network throughout Massachusetts and Rhode Island.
Coordinate Your IVIG Care With Suite Life
For multiple myeloma patients, IVIG therapy can be a critical part of staying healthy during cancer treatment. Working with an experienced infusion team ensures that each session is safe, comfortable, and on schedule.
Suite Life Health and Wellness provides specialized immunology infusion services, including IVIG, for patients across Massachusetts and Rhode Island. Request an appointment today and let the Suite Life team support your treatment plan in coordination with your oncologist.
Frequently Asked Questions
What is IVIG used for in multiple myeloma patients?
IVIG is used as an antibody replacement therapy for multiple myeloma patients with low immunoglobulin levels or recurrent infections. It helps protect against bacterial, viral, and fungal infections by replacing the antibodies the immune system can no longer produce.
How often will I need IVIG infusions?
Most multiple myeloma patients receive IVIG every 3 to 4 weeks, though your oncologist will determine the schedule based on your IgG levels, infection history, and overall treatment plan.
Are there infusion centers near me that provide IVIG for cancer patients?
Yes. Suite Life Health and Wellness provides IVIG infusions for cancer patients, including those with multiple myeloma, at convenient locations across Massachusetts and Rhode Island, including Westfield and Westborough. Your oncologist can refer you to an infusion center near you.
Are there side effects of IVIG therapy?
The most common side effects are mild and include headache, fatigue, muscle aches, and low-grade fever. Severe reactions are rare. Slower infusion rates and premedications can help reduce side effects.
Does IVIG treat the cancer itself?
No. IVIG does not treat multiple myeloma directly. Instead, it supports the immune system by replacing missing antibodies and reducing infection risk while patients undergo other myeloma treatments managed by their oncologist.
